Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
New nanoencapsulation research reveals enhanced neuroprotection against brain injury. Learn implications for thymosin beta 4 injury treatment approaches.
By Peptide Association Research Team
New research reveals how thymosin alpha 1 immune modulation may help combat HIV latency through IL-15 pathway activation in laboratory studies.
By Peptide Association Research Team
New research reveals thymosin alpha 1 immune therapy combined with IL-15 may help reverse immune cell aging in hepatocellular carcinoma. Learn the implications.
By Peptide Association Research Team
New research on SS-31 peptide reveals neuroprotective mechanisms in stroke models. Study findings on mitochondrial peptide therapy for brain health.
By Peptide Association Research Team
New research on SS-31 Elamipretide and NAC shows promising airway protection mechanisms. Learn implications for thymosin alpha 1 immune support therapy.
By Peptide Association Research Team